Evan A Schwartz

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Molecular Dynamics Simulations

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Evan A Schwartz, Jack P K Bravo, Mohd Ahsan, Luis A Macias, Caitlyn L McCafferty, Tyler L Dangerfield, Jada N Walker, Jennifer S Brodbelt, Giulia Palermo, Peter C Fineran, Robert D Fagerlund, David W Taylor
RNA targeting and cleavage by the type III-Dv CRISPR effector complex. Nature communications 15 (1) (2024)
Evan A Schwartz, Jack P K Bravo, Mohd Ahsan, Luis A Macias, Caitlyn L McCafferty, Tyler L Dangerfield, Jada N Walker, Jennifer S Brodbelt, Giulia Palermo, Peter C Fineran, Robert D Fagerlund, David W Taylor
RNA targeting and cleavage by the type III-Dv CRISPR effector complex. Nature communications 15 (1) (2024)
Evan A Schwartz, Jack P K Bravo, Mohd Ahsan, Luis A Macias, Caitlyn L McCafferty, Tyler L Dangerfield, Jada N Walker, Jennifer S Brodbelt, Giulia Palermo, Peter C Fineran, Robert D Fagerlund, David W Taylor
RNA targeting and cleavage by the type III-Dv CRISPR effector complex. Nature communications 15 (1) (2024)
Evan A Schwartz, Jack P K Bravo, Mohd Ahsan, Luis A Macias, Caitlyn L McCafferty, Tyler L Dangerfield, Jada N Walker, Jennifer S Brodbelt, Giulia Palermo, Peter C Fineran, Robert D Fagerlund, David W Taylor
RNA targeting and cleavage by the type III-Dv CRISPR effector complex. Nature communications 15 (1) (2024)
Evan A Schwartz, Jack P K Bravo, Mohd Ahsan, Luis A Macias, Caitlyn L McCafferty, Tyler L Dangerfield, Jada N Walker, Jennifer S Brodbelt, Giulia Palermo, Peter C Fineran, Robert D Fagerlund, David W Taylor
RNA targeting and cleavage by the type III-Dv CRISPR effector complex. Nature communications 15 (1) (2024)
Evan A Schwartz, Jack P K Bravo, Mohd Ahsan, Luis A Macias, Caitlyn L McCafferty, Tyler L Dangerfield, Jada N Walker, Jennifer S Brodbelt, Giulia Palermo, Peter C Fineran, Robert D Fagerlund, David W Taylor
RNA targeting and cleavage by the type III-Dv CRISPR effector complex. Nature communications 15 (1) (2024)